-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Optimizing Hydroxyurea Therapy in Sickle Cell Disease

Program: Education Program
Session: Optimizing Therapy in Sickle Cell Disease
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Chapin Theater (W320), Level 3 (Orange County Convention Center)
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Hall E1, Level 2 (Orange County Convention Center)

Russell E. Ware, MD, PhD

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Disclosures: Ware: Biomedomics: Research Funding ; Bayer Pharmaceuticals: Consultancy ; Eli Lilly: Other: DSMB membership ; Bristol Myers Squibb: Research Funding . Off Label Use: Hydroxyurea for children with SCA.

See more of: Optimizing Therapy in Sickle Cell Disease
See more of: Education Program
<< Previous Presentation | Next Presentation >>